Advertisement

Potential Use of LHRH and Analogues: Clinical Implications

  • J. Sandow
  • K. Engelbart
  • W. von Rechenberg
Part of the Biochemical Endocrinology book series (BIOEND)

Abstract

The development of LHRH-related peptides has been very rapid since the elucidation in 1971 of the structure of LHRH (see reviews by Schally et al., 1981, Yen, 1983, Swerdloff and Heber, 1983, Sandow, 1983). Today, the established clinical role for synthetic LHRH is in stimulation of gonadal function by pulsatile activation of gonadotrophin secretion (Knobil, 1980, Leyendecker et al., 1980, Hoffman and Crowley, 1982). LHRH analogues are predominantly used for reversible suppression of gonadal steroid secretion. The therapeutic potential of agonists and antagonists of LHRH is exerted through different mechanisms of action. Agonists stimulate gonadotrophin release at low doses, when given at suitable intervals so that pituitary sensitivity can recover between stimulations. At higher doses, they suppress pituitary function when given repeatedly. Several important clinical indications are now studied based on reversible suppression of pituitary and gonadal function by agonists. The LHRH antagonists block the action of endogenous and exogenous LHRH for extended time periods, and cause reversible pituitary-gonadal involution without a stimulation phase. Antagonists are now studied in preclinical animal models, and the inhibitory activity has been confirmed in humans

Keywords

Nasal Spray Precocious Puberty Gonadal Steroid Cyproterone Acetate LHRH Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Badger, T.M., Loughlin, J.S. and Naddaff, P.G. (1983): The lutei-nizing hormone-releasing hormone (LHRH)-desensitized rat pituitary: luteinizing hormone responsiveness to LHRH in vitro. Endocrinology 112: 793–799PubMedCrossRefGoogle Scholar
  2. Baumann, R., Kuhl, H., Taubert, H.D. and Sandow, J. (1980): Ovulation inhibition by daily i.mó administration of a highly active LHRH analog (D-Ser(TBU) -LHRH(1–9)nonapeptide-ethylamide). Contraception 21: 191–197PubMedCrossRefGoogle Scholar
  3. Bergquist, C., Nillius, S.J., Bergh, T., Skarin, G. and Wide, L. (1979): Inhibitory effects on gonadotropin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. Acta Endocrinol. (Kbh.) 91: 601–608PubMedGoogle Scholar
  4. Bergquist, C., Nillius, S.J. and Wide, L. (1982): Intranasal LHRH agonist treatment for inhibition of ovulation in women: clinical aspects. Clin. Endocrinol. 17: 91–98CrossRefGoogle Scholar
  5. Bint Akhtar, F., Marshall, G.R., Wickings, E.J. and Nieschlag, E. (1983): Reversible induction of azoospermia in rhesus monkeys by constant infusion of a gonadotropin-releasing hormone agonist using osmotic minipumps. J. Clin. Endocrinol. Metab. 56: 534–540CrossRefGoogle Scholar
  6. Borgmann, V., Hardt, W., Schmidt-Gollwitzer, M., Adenauer, H. and Nagel, R. (1982): Sustained suppression of testosterone production by the luteinizing-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach? Lancet (May 82 ): 1097–1099CrossRefGoogle Scholar
  7. Bremner, W.J., Matsumoto, A.M., Sussman, A.M. and Paulsen, C.A. (1981): Follicle-stimulating hormone and human spermatogenesis. J. Clin. Invest. 68: 1044–1052Google Scholar
  8. Casper, R.F. and Yen, S.S.C. (1981): Menopausal flushes: effect of pituitary gonadotropin desensitization by a potent luteinizing hormone-releasing factor agonist. J. Clin. Endocrinol. Metab. 53: 1056–1058Google Scholar
  9. Chang, R.J., Laufer, L.R., Meldrum, D.R., DeFazio, J., Lu, J.K.H., Vale, W.W., Rivier, J.E. and Judd, H.L. (1983): Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J. Clin. Endocrinol. Metab. 56: 897–903Google Scholar
  10. Clayton, R.N. (1982): GnRH modulation of its own pituitary receptors: evidence for biphasic regulation. Endocrinology 111: 152–161PubMedCrossRefGoogle Scholar
  11. Comite, F., Cutler Jr., G.B., Rivier, J., Vale, W.W., Loriaux, D.L. and Crowley Jr., W.F. (1981): Short-term treatment of idiopathic precocious puberty with a long-acting analogue of LHRH. New Engl. J. Med. 305: 1546–1550Google Scholar
  12. Corbin, A. (1982): From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents. Yale J. Biol. Med. 55: 27–47Google Scholar
  13. Fraser, H.M. (1983): Effect of treatment for one year with a luteinizing hormone-releasing hormone agonist on ovarian, thyroidal, and adrenal function and menstruation in the stumptailed monkey (macaca arctoides). Endocrinology 112: 245–253PubMedCrossRefGoogle Scholar
  14. Fraser, H.M., Laird, N.C. and Blakely, D.M. (1980): Decreased pituitary responsiveness and inhibition of the luteinizing hormone surge and ovulation in the stumptailed monkey (ma-caca arctoides) by chronic treatment with an agonist of luteinizing hormone-releasing hormone. Endocrinology 106: 452–457PubMedCrossRefGoogle Scholar
  15. Furr, B.J.A. and Nicholson, R.I. (1982): Use of analogues of LHRH for the treatment of cancer. J. Reprod. Fertil. 64: 529–539Google Scholar
  16. Hardt, W., Schmidt-Gollwitzer, K., Nevinny-Stickel, J. and SchmidtGollwitzer, M. (1982): Fortschritte in der kontrazeptiven Anwendung des LHRH-Agonisten Buserelin: diskontinuierliche Medikation mit gestageninduzierter Abbruchblutung. Geburtshilfe Frauenheilkd. 42: 874–877PubMedCrossRefGoogle Scholar
  17. Hoffman, A.R. and Crowley, W.F. (1982): Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. New Engl. J. Med. 307: 1237–1241Google Scholar
  18. Klijn, J.G.M. and de Jong, F.H. (1982): Treatment with a luteinizing-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet (May 1982): 1213–1216Google Scholar
  19. Knobil, E. (1980): The neuroendocrine control of the menstrual cycle. Recent Prog. Horm. Res. 36: 53–88Google Scholar
  20. Labrie, F., Dupont, A., Bélanger, A., Cusan, L., Lacourciére, Y., Monfette, G., Laberge, J.G., Emond, J.P., Fazekas, A.T.A., Raynaud, J.P. & Husson, J.M. (1982): New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. J. Clin. Invest. Med. 5: 267–275Google Scholar
  21. Lemay, A. and Quesnel, G. (1982): Potential new treatment of endometriosis - reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a LHRH agonist. Fertil. Steril. 38: 376–377Google Scholar
  22. Leyendecker, G., Wildt, L. and Hansmann, M. (1980): Pregnancies following chronic intermittent (pulsatile) administration of GnRH by means of a portable pump (Zyklomat). A new approach in the treatment of infertility in hypothalamic amenorrhea. J. Clin. Endocrinol. Metab. 51: 1214–1216Google Scholar
  23. Meldrum, D.R., Chang, R.J., Lu, J., Vale, W., Rivier, J. and Judd, H.L. (1982): “Medical oophorectomy” using a long-acting GnRH agonist - a possible new approach to the treatment of endometriosis. J. Clin. Endocrinol. Metab. 54: 1081–1083Google Scholar
  24. Redding, T.W. and Schally, A.V. (1981): Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp analogue of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 78: 6509–6512Google Scholar
  25. Sandow, J. (1982): Inhibition of pituitary and testicular function by LHRH analogues. In: Progress towards a male contra-ceptive (eds. S.L. Jeffcoate & M. Sandler ), John Wiley and Sons Ltd., London, pp. 19–39Google Scholar
  26. Sandow, J. (1983): Clinical applications of LHRH and its analogues. Clin. Endocrinol. 18: 571–592Google Scholar
  27. Sandow, J., Kuhl, H., Jerzabek, G., Kille, S. and Rechenberg, W.v. (1982): The reproductive pharmacology and contraceptive application of LHRH and its analogues. In: The Gonadotropins: Basic Science and Clinical Aspects in Females (eds. C. Flamigni & J.R. Givens ), Academic Press, London, pp. 77–105Google Scholar
  28. Schally, A.V., Arimura, A. and Coy, D.H. (1981): Recent approaches to fertility control based on derivates of LHRH. Vitam. Horm. 38: 257–310Google Scholar
  29. Schmidt-Gollwitzer, M., Hardt, W., Schmidt-Gollwitzer, K. and Nevinny-Stickel, J. (1981): Influence of the LHRH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control? Contraception 23: 187–196PubMedCrossRefGoogle Scholar
  30. Sharpe, R.M. (1982): Cellular aspects of the inhibitory actions of LHRH on the ovary and testis. J. Reprod. Fertil. 64: 517–527PubMedCrossRefGoogle Scholar
  31. Skarin, G., Nillius, S.J. and Wide, L. (1982): Early follicular phase luteinizing hormone-releasing hormone agonist administration–effects on follicular maturation and corpus luteum function in women. Contraception 25: 31–39PubMedCrossRefGoogle Scholar
  32. Swerdloff, R.S. and Heber, D. (1983): Superactive gondotropin-re- leasing hormone agonists. Ann. Rev. Med. 34: 491–500Google Scholar
  33. Tolis, G., Ackman, D., Apostolos, S., Metha, A., Labrie, F., Fazekas, A.T.A., Comaru-Schally, A.M. & Schally, A.V. (1982): Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonist. Proc. Natl. Acad. Sci. USA 79: 1658–1662Google Scholar
  34. Vickery, B.H. (1981): Physiology and antifertility effects of LHRH and agonistic analogs in male animals. In: LHRH peptides as female and male contraceptives (eds. G.I. Zatuchni, J.D. Shelton & J.J. Sciarra ), Harper & Row, Philadelphia, pp. 275–290Google Scholar
  35. Waxman, J.H., Wass, J.A.H., Hendry, W.F., Whitfield, H.N., Besser, G.M., Malpas, J.S. and Oliver, R.T.D. (1983): Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br. Med. J. 286: 1309–1312Google Scholar
  36. Yeo, T., Grossman, A., Belchetz, P. and Besser, G.M. (1981): Response of LH from colums of dispersed rat pituitary cells to a highly potent analogue of LHRH. J. Endocrinol. 91: 33–41PubMedCrossRefGoogle Scholar
  37. Yen, S.S.C. (1983): Clinical applications of gonadotropin-releasind hormone and gonadotropin-feleasing hormone analogs. Fertil. Steril. 39: 257–266Google Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • J. Sandow
    • 1
  • K. Engelbart
    • 1
  • W. von Rechenberg
    • 1
  1. 1.Hoechst AGFrankfurt 80Germany, F.R.

Personalised recommendations